FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation